Navigation Links
Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
Date:7/12/2011

ty and mechanism of action of APD811; the potential of APD811 and orally bioavailable, non-prostanoid prostacyclin receptor agonists in general; future study and evaluation of APD811; Arena's commitment to advance its pipeline; the therapeutic indication of Arena's most advanced drug candidate; and Arena's beliefs, focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: there was a small safety margin from the no observed adverse effect level to significant adverse events in preclinical studies of APD811, and APD811 could have an unacceptable safety and efficacy profile in humans; the timing of regulatory review and approval is uncertain; the risk that data and other information related to Arena's research and development programs may not meet safety or efficacy requirements or otherwise be sufficient for regulatory approval; Arena's response to the CRL for the lorcaserin NDA or submission of a Marketing Authorization Application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; the FDA may request other information prior to or after Arena submits such response or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; Arena's ability to obtain
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
2. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
3. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
4. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
5. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
6. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
7. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
8. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
9. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
11. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... 19, 2014 Große Pharmafirmen ... Das Problem dabei ist, dass große Pharmafirmen nicht ... zu teilen. Es war deshalb nicht ... uns umso mehr, dass es uns gelungen ist! ... Kühlketten aufzuschreiben - mit einem Vorbehalt - einige ...
(Date:10/17/2014)... OAKS, Calif. , Oct. 17, 2014  Amgen ... of R. Sanders Williams , M.D., president of ... Mahley Distinguished Professor.  "We are pleased ... Amgen Board," said Robert A. Bradway , chairman ... and distinguished experience in academic medicine and his direct ...
(Date:10/17/2014)... , October 17, 2014 /PRNewswire/ ... and Markets ( http://www.researchandmarkets.com/research/rxznjk/micro_market ) has announced ... Monitor : North American Automated External ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The report ... 2008-2018 analyzes the market of devices ...
Breaking Medicine Technology:Vergleichsbericht zu Pharma-Kühlketten und CRT 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2
(Date:10/20/2014)... Norristown, PA (PRWEB) October 20, 2014 ... of Matthew Voicheck as Assistant Director of their ... integral role in managing the innovative turnkey drug ... trials. , Matthew brings over 12 years of ... He joins Myoderm at the peak of their ...
(Date:10/20/2014)... October 20, 2014 Final Cut Pro X ... of the Citrus theme for FCPX filmmakers . , ... to describe the Citrus theme” Says Christina Austin, CEO of ... look so professional.” , Citrus comes with all the tools ... template are: four transitions for added style, a title screen ...
(Date:10/20/2014)... USA (PRWEB) October 20, 2014 Do ... track interventions? Here comes a wonderful app Metassessor for ... app development company helped its client “Intervention Development ... efficiently. The app is designed for iOS 4.3 or ... touch. This app is optimized for iPhone 5. It ...
(Date:10/19/2014)... 2014 This report provides comprehensive ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ... features on late-stage and discontinued projects. , Partial ...
(Date:10/19/2014)... Visual Impact Frequency Training - a ... to the public generating a frenzied buzz of ... community. The commotion surrounding the program's launch has ... an investigative review. , "Many gym-goers are familiar ... known as a training 'plateau' where they are ...
Breaking Medicine News(10 mins):Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2
... ALEXANDRIA, Va., Sept. 24 - An editorial,published ... Dental Research (JDR),focuses on the global theme issue ... for Dental Research (IADR) President,Deborah Greenspan and IADR ... of Orofacial Sciences, School of Dentistry, The AIDS ...
... Companies Investing in R&D Shows Revenue Derived ... of Total Revenue in 2006, PHILADELPHIA and ... International Ltd. (CMR), a Thomson business, today,announced it ... an indispensable reference and business planning tool for,decision ...
... announced today that the U.S. Food and Drug ... 360(TM) Orbital Atherectomy System (OAS),for removing plaque blockages ... device offers a promising new alternative for treating ... Disease,PAD. The clearance follows the successful completion ...
... the Institute of Bioengineering and Nanotechnology (IBN), Institute of ... Singapore (GIS) have successfully developed a miniaturized device that ... flu (H5N1) virus. , If successfully commercialized, this ... surveillance of nascent avian flu epidemic. , According to ...
... The Iacocca Foundation and S.E.VEN, BOSTON, Sept. 24 ... has added finding a cure for diabetes and,alleviating world ... of The,Iacocca Foundation and S.E.VEN. "As communicators, we ... not driven by dollars, but by a commitment,to truly ...
... Md., Sept. 24 MedImmune, Inc. announced,today that ... to GlaxoSmithKline to support the development and construction ... vaccines. Reverse,genetics is a method by which viruses ... DNA. For potential pandemic influenza vaccines, reverse,genetics can ...
Cached Medicine News:Health News:Dental Researchers Participate in Global Awareness Initiative 2Health News:2007/2008 Pharmaceutical R&D Factbook Published by CMR International is Now Available 2Health News:2007/2008 Pharmaceutical R&D Factbook Published by CMR International is Now Available 3Health News:New Device for Clearing Blocked Arteries in the Legs Receives FDA Clearance for Peripheral Use - Procedures Performed Across the US Within First 48 Hours 2Health News:New Device for Clearing Blocked Arteries in the Legs Receives FDA Clearance for Peripheral Use - Procedures Performed Across the US Within First 48 Hours 3Health News:Lab-on-chip testing for 'bird flu' developed by Singapore scientists 2Health News:Small Army Takes on Cure for Diabetes and New Approach to Ending World Poverty with Addition of Non-Profit Accounts 2Health News:MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production 2
... AvantGard Low Binding 20l Barrier Tips. Low ... DNA and proteins bound to the tip. Most ... which means the focus is on liquid not ... focuses on low binding which reduces the binding ...
... tips eliminate false signals and contamination ... tested, Promega Barrier Tips offer performance ... nucleic acids (PCR(a)), radioactive isotopes, tissue ... serological specimens. , ,Promega Barrier Tips ...
... Aerosol Resistant Tips offer a safe alternative ... are designed for applications such as PCR(a), ... addition, ART Tips are excellent for tissue ... studies. ART Tips prevent aerosol contaminants and ...
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
Medicine Products: